Literature DB >> 24334724

Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease.

Anne Gerschütz1, Helmut Heinsen2, Edna Grünblatt3, Anne Kristin Wagner1, Jasmin Bartl3, Christoph Meissner4, Andreas J Fallgatter5, Safa Al-Sarraj6, Claire Troakes6, Isidro Ferrer7, Thomas Arzberger8, Jürgen Deckert2, Peter Riederer2, Matthias Fischer2, Thomas Tatschner9, Camelia Maria Monoranu1.   

Abstract

The hallmarks of sporadic Alzheimer's disease (AD) are extracellular amyloid deposits, intracellular neurofibrillary tangles (NFTs), and neuronal death. Hyperphosphorylation of tau is a key factor in the generation of NFTs. Mitogen activated protein kinase 1 (MAPK1) and protein kinase C beta (PRKCB) are thought to play a role in hyperphosphorylation, and PRCKB is thought to be involved in hypoxic stress and vascular dysfunction, and to trigger MAPK phosphorylation pathways. We performed single-cell analyses of neurons with different vulnerabilities to AD-related changes. Using quantitative PCR (qPCR), we measured the levels of MAPK1 and PRKCB transcript in CA1 (high vulnerability), CA2 pyramidal cells from the hippocampus, granule cells from the cerebellum (low vulnerability), and neurons from the brain stem (nucleus tractus spinalis nervi trigemini, characterized by early neurophysiological deficits) at progressive Braak stages compared to age-matched controls. The highly vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1 levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages. MAPK1 and PRKCB levels were low in the brainstem and cerebellum. We propose that alterations in the expression of these two genes occur early in the pathogenesis of AD in a region-specific manner. In addition, multiple signal transduction pathways need to be affected to result in AD instead of physiological aging.

Entities:  

Keywords:  Alzheimer's disease; MAPK1; PRKCB; neurodegeneration; selective vulnerability; signal transduction pathway

Mesh:

Substances:

Year:  2014        PMID: 24334724     DOI: 10.3233/JAD-131280

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  20 in total

1.  Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease.

Authors:  Anna Antonell; Albert Lladó; Raquel Sánchez-Valle; Coral Sanfeliu; Teresa Casserras; Lorena Rami; Cristina Muñoz-García; Adrià Dangla-Valls; Mircea Balasa; Patricia Boya; Susana G Kalko; José Luis Molinuevo
Journal:  Mol Neurobiol       Date:  2015-10-28       Impact factor: 5.590

Review 2.  Common mechanisms of Alzheimer's disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration.

Authors:  Brandon P Lucke-Wold; Ryan C Turner; Aric F Logsdon; James W Simpkins; Daniel L Alkon; Kelly E Smith; Yi-Wen Chen; Zhenjun Tan; Jason D Huber; Charles L Rosen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

4.  Single Cell Multiplex Protein Measurements through Rare Earth Element Immunolabeling, Laser Capture Microdissection and Inductively Coupled Mass Spectrometry.

Authors:  Amir Liba; Jonathan Wanagat
Journal:  J Cytol Histol       Date:  2014-10-30

Review 5.  Selective vulnerability in neurodegenerative diseases.

Authors:  Hongjun Fu; John Hardy; Karen E Duff
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

Review 6.  Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies.

Authors:  Brandon Dickey; Leelavathi N Madhu; Ashok K Shetty
Journal:  Pharmacol Ther       Date:  2020-10-24       Impact factor: 12.310

7.  Chronic Oxidative Stress, Mitochondrial Dysfunction, Nrf2 Activation and Inflammation in the Hippocampus Accompany Heightened Systemic Inflammation and Oxidative Stress in an Animal Model of Gulf War Illness.

Authors:  Geetha A Shetty; Bharathi Hattiangady; Dinesh Upadhya; Adrian Bates; Sahithi Attaluri; Bing Shuai; Maheedhar Kodali; Ashok K Shetty
Journal:  Front Mol Neurosci       Date:  2017-06-14       Impact factor: 5.639

Review 8.  Copy Number Variations in Amyotrophic Lateral Sclerosis: Piecing the Mosaic Tiles Together through a Systems Biology Approach.

Authors:  Giovanna Morello; Maria Guarnaccia; Antonio Gianmaria Spampinato; Valentina La Cognata; Velia D'Agata; Sebastiano Cavallaro
Journal:  Mol Neurobiol       Date:  2017-01-24       Impact factor: 5.590

9.  Proteomic Analysis of Hippocampus in a Mouse Model of Depression Reveals Neuroprotective Function of Ubiquitin C-terminal Hydrolase L1 (UCH-L1) via Stress-induced Cysteine Oxidative Modifications.

Authors:  Jung-Eun Choi; Jae-Jin Lee; Wonmo Kang; Hyun Jung Kim; Jin-Hwan Cho; Pyung-Lim Han; Kong-Joo Lee
Journal:  Mol Cell Proteomics       Date:  2018-06-29       Impact factor: 5.911

10.  Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.

Authors:  Mariet Allen; Xue Wang; Daniel J Serie; Samantha L Strickland; Jeremy D Burgess; Shunsuke Koga; Curtis S Younkin; Thuy T Nguyen; Kimberly G Malphrus; Sarah J Lincoln; Melissa Alamprese; Kuixi Zhu; Rui Chang; Minerva M Carrasquillo; Naomi Kouri; Melissa E Murray; Joseph S Reddy; Cory Funk; Nathan D Price; Todd E Golde; Steven G Younkin; Yan W Asmann; Julia E Crook; Dennis W Dickson; Nilüfer Ertekin-Taner
Journal:  Acta Neuropathol       Date:  2018-08-22       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.